Built on exceptional science and driven to improve patients’ lives, Byondis is an independent biopharmaceutical research and development (R&D) company creating innovative precision medicines targeting intractable cancers and autoimmune diseases. Byondis employs the latest insights in tumor biology and immunology to search for new molecular targets and develop new mechanisms for antibody-drug conjugates (ADCs), monoclonal antibodies (mAbs) and small molecule programs. With in-house GMP production and conjugation facilities up to early commercial launch scale. We have a dedicated team of about 400 highly qualified employees, working in our state-of-the-art R&D and manufacturing facilities on our Nijmegen campus in the Netherlands.

Categorieën